Omiganan (topical cationic peptide) to be trialled as rosacea treatment

Written by on October 6, 2006 in clinical trials with 1 Comment

A new topical treatment for acne, known generically as Omiganan, is to be trialled for rosacea. The treatment is known as a topical cationic peptide. This treatment has anti-inflammatory properties that were promising for acne. Now the developers are planning to trial it next year against rosacea.

From MIGENIX Reports First Quarter Fiscal Year 2007 Financial Results

Omiganan (CLS-001/MX-594AN; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS-001, is pursuing rosacea as its first indication for development and plans to initiate and complete a phase II clinical trial in 2007.

From About MX-594AN and Acne

MX-594AN is an antimicrobial cationic peptide in development as a topical prescription treatment for mild to moderate acne vulgaris. MX-594AN has completed five clinical trials in the US – three Phase I studies and two Phase II studies. The Phase II trials demonstrated evidence of efficacy against all acne lesion types.

From Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. FEMS Microbiol Lett. 2006 Apr;257(1):1-6, Marta Guarna M, Coulson R, Rubinchik E., MIGENIX, Vancouver, BC, Canada.

Cationic antimicrobial peptides exhibit potent antimicrobial activity against clinically relevant microorganisms including Propionibacterium acnes. Recent studies showed that, in addition to the antimicrobial activity, these peptides can exhibit an anti-inflammatory effect. These properties make cationic peptides attractive drug candidates for the treatment of acne vulgaris, a disease with both bacterial and inflammatory components. This review focuses on the anti-inflammatory activity of cationic antimicrobial peptides and its application for the treatment of acne vulgaris. The anti-inflammatory activity of cationic peptides in acne vulgaris can be explained by their ability to both bind proinflammatory bacterial factors (e.g. lipoteichoic acid), sequestering them from the site of inflammation, and to inhibit the secretion of proinflammatory cytokines (e.g. tumor necrosis factor-alpha, IL-1) by host cells. These anti-inflammatory effects combined with potent antimicrobial activity may translate into a novel therapeutic option for acne vulgaris.

From Omiganan Pentahydrochloride in the Front Line of Clinical Applications of Antimicrobial Peptides, Recent Patents on Anti-Infective Drug Discovery, Volume 1, Number 2, June 2006, pp. 201-207(7), Melo, Manuel N.; Dugourd, Dominique; Castanho, Miguel A.R.B

Ribosomally synthesized antimicrobial peptides have very wide killing spectra and bacterial resistance to these peptides seems to be a rare phenomenon. Indolicidin is a ribosomally synthesized antimicrobial peptide that served as a template to omiganan, which is in development for the prevention of catheter-related bloodstream infections; clinical trials also proved its efficiency against acne vulgaris. Omiganan is the most advanced molecule in the front line of clinical applications of antimicrobial peptides. The mode and site of action of omiganan are not yet settled although its interaction with membranes is known to play a fundamental role. The biochemical and biophysical foundations for the action of indolicidin and its analogues are reviewed in this paper, as well as the clinical application of omiganan. The in vitro efficiency tests and the outcome of clinical trials are addressed. Altogether, despite the very specific use of omiganan as a topical antibiotic, it has the potential of being a pioneer of a new generation of antibiotics that carry the promise of ending the multi-resistance problem.

Related Articles

Read more about: clinical trials

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. mary says:


Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.